Meeting
2022 ASCO Annual Meeting
MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas.
Authors
Mrinal M. Gounder
Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY
Mrinal M. Gounder , Gary K. Schwartz , Robin Lewis Jones , Sant P. Chawla , Victoria S. Chua-Alcala , Silvia Stacchiotti , Andrew J. Wagner , Gregory Michael Cote , Robert G Maki , Hanna Kosela-Paterczyk , Dale Randall Shepard , Naisargee Shah , Richard Bryce , Robert Charles Doebele , Shreyaskumar Patel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT04979442
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS11589)
DOI
10.1200/JCO.2022.40.16_suppl.TPS11589
Abstract #
TPS11589
Poster Bd #
489b
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Whole exome sequencing (WES) of metastatic leiomyosarcoma (LMS) and liposarcoma (LPS) and correlation of genomic aberrations with clinical outcomes in the phase III randomized trial of trabectedin (T) vs. dacarbazine (D).
First Author: Gurpreet Kapoor
Poster
2024 ASCO Gastrointestinal Cancers Symposium
DIsCOvER: A multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to investigate the efficacy and safety of dronabinol in the improvement of chemotherapy-induced and tumor-related symptoms in patients with locally advanced or metastatic pancreas cancer during first-line chemotherapy.
First Author: Felix Keil
Poster
2023 ASCO Annual Meeting
A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma.
First Author: Daniel Olson
Poster
2023 ASCO Annual Meeting
A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with solid tumors: Safety and efficacy in patients with dedifferentiated liposarcoma (DDLPS).
First Author: Patricia LoRusso